Evidence map›Paper›PMID 41540063›Full record

ArticleNature communications2026

Improved in vivo gene knockout with high specificity using multiplexed Cas12a sgRNAs.

Fillip Port, Martha A Buhmann, Jun Zhou, Mona Stricker, Alexander Vaughan-Brown, Ann-Christin Michalsen, Eva Roßmanith, Amélie Pöltl, Lena Großkurth, Julia Huber and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fillip PortDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. f.port@dkfz.de.ORCID http://orcid.org/0000-0002-5157-4835
Martha A BuhmannDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jun ZhouDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0009-0003-7848-3612
Mona StrickerDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Alexander Vaughan-BrownDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0009-0008-6561-5758
Ann-Christin MichalsenDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Eva RoßmanithDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Amélie PöltlDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lena GroßkurthDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Julia HuberDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Laura B Menendez KuryDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bea WeberbauerDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maria HüblDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Elli PuscherDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Florian HeigwerDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8230-1485
Michael BoutrosDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.boutros@dkfz.de.ORCID http://orcid.org/0000-0002-9458-817X

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) SFB1324EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC-DECODE
6 · The paper itself

Abstract

CRISPR nuclease-mediated gene knock-out is limited by suboptimal sgRNAs, inaccessible target sites, and undesired repair outcomes. Here, we present a Cas12a-based system in Drosophila that targets each gene with four sgRNAs to overcome these limitations. Multiplexed sgRNAs act through redundancy and synergism, frequently creating deletions between target sites and increasing the fraction of loss-of-function mutations. We show that multiplexed gene targeting is well tolerated and does not cause widespread proximity effects. To visualize CRISPR-nuclease activity in living animals, we developed a screening assay and used it to assess Cas12a activity across 33% of the Drosophila genome in combination with over 2000 sgRNAs. This revealed remarkably high on-target (>99%) and very low (<1%) off-target activity of multiplexed Cas12a sgRNA arrays. Quantitative side-by-side comparisons with current Cas9-based systems targeting over 100 genes in parallel demonstrate that multiplexed Cas12a gene targeting achieves superior performance and reveals phenotypes missed by established methods. The system described here provides a framework for reliable gene knock-out in multicellular systems.

Indexed as

Bacterial ProteinsCRISPR-Associated ProteinsCRISPR-Cas SystemsEndodeoxyribonucleasesGene Knockout TechniquesRNA, Guide, CRISPR-Cas SystemsAnimalsDrosophilaDrosophila melanogasterBacterial ProteinsCas12a proteinCRISPR-Associated ProteinsEndodeoxyribonucleasesRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID41540063
PMCPMC12827956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.